Evidence map›Paper›PMID 39131076›Full record

ReviewJournal of the Society for Cardiovascular Angiography & Interventions

Medical Management and Device-Based Therapies in Chronic Heart Failure.

Andrew H Nguyen, Madelyn Hurwitz, Jacob Abraham, Vanessa Blumer, M Casey Flanagan, A Reshad Garan, Manreet Kanwar, Rachna Kataria, Jamie L W Kennedy, Ajar Kochar and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the Society for Cardiovascular Angiography & Interventions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Andrew H NguyenInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
Madelyn HurwitzSchool of Medicine, University of Virginia, Charlottesville, Virginia.
Jacob AbrahamCenter for Cardiovascular Analytics, Research & Data Science, Providence-St. Joseph Health, Portland, Oregon.
Vanessa BlumerInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
M Casey FlanaganInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
A Reshad GaranDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Manreet KanwarCardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania.
Rachna KatariaLifespan Cardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Jamie L W KennedyInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
Ajar KocharDivision of Cardiology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jaime Hernandez-MontfortAdvanced Heart Disease Program, Baylor Scott & White Health, Temple, Texas.
Mohit PahujaDepartment of Cardiology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Palak ShahInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
Matthew W SherwoodInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
Behnam N TehraniInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
Saraschandra VallabhajosyulaSection of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Navin K KapurThe CardioVascular Center, Tufts Medical Center, Boston, Massachusetts.
Shashank S SinhaInova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Major advancements in optimal guideline-directed medical therapy, including novel pharmacological agents, are now available for the treatment of chronic HF including HF with reduced ejection fraction and HF with preserved ejection fraction. Despite these efforts, there are several limitations of medical therapy including but not limited to: delays in implementation and/or initiation; inability to achieve target dosing; tolerability; adherence; and recurrent and chronic costs of care. A significant proportion of patients remain symptomatic with poor HF-related outcomes including rehospitalization, progression of disease, and mortality. Driven by these unmet clinical needs, there has been a significant growth of innovative device-based interventions across all HF phenotypes over the past several decades. This state-of-the-art review will summarize the current landscape of guideline-directed medical therapy for chronic HF, discuss its limitations including barriers to implementation, and review device-based therapies which have established efficacy or demonstrated promise in the management of chronic HF.

Indexed as

devicesheart failuremedical management

Identifiers

PMID39131076
PMCPMC11308856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.